Abstract
211 patients with various stages of breast cancer were studied by both the CA 15.3 and CEA markers to assess whether the latter may increase the screening sensitivity of the former. While both markers were equally specific, CA 15.3 was seen to be much more sensitive than CEA (p<0.0001). Also, the addition of the CEA did not add appreciably (7%) to positive detection by CA 15.3. There appears to be no advantage to including CEA in a marker panel to follow the course of breast carcinoma.
This is a preview of subscription content, log in via an institution to check access.
References
Wilkens J, Kroezen V, Bonfrer JMG, Bruning PF, Hilgers J, van Eijkeren A: A sandwich radioimmunoassay for a new antigen (MAM-6) present in the sera of patients with metastasized carcinomas.In Peeters H (ed) Protides of the Biological Fluids, 32. Pergamon, Oxford, 1984, pp 651–653
Kufe D, Inghirami G, Abe M, Hayes P, Justi-Wheeler H, Schlom J: Differential reactivity of a novel monoclonal antibody (DF-3) with human malignant versus benign breast tumors. Hybridoma 3: 223–232, 1984
Schlom J, Greiner J, Hand PH, Colcher D, Inghirami G, Weeks M, Pestka S, Fisher PB, Noguchi P, Kufe D: Monoclonal antibodies to breast cancer associated antigens as potential reagents in the management of breast cancer. Cancer 54: 2777–2794, 1984
Hayes DF, Zurawski VR, Kufe DW: Comparison of circulating CA 15.3 and carcinoembryonic antigen levels in patients with breast cancer. J Clin Oncol 4: 1542–1550, 1986
Namer M, Krebs BP, Hery M, Aubanel M, Khater R, Frenay M: CEA versus CA 15.3 as markers for metastasized breast cancer. Proc ASCO 5: 24, 1986
Colomer R, Sole LA, Navarro M, Encabo G, Ruibal A, Salvador L: CA 15.3: Early results of a new breast cancer marker. Anticancer Res 6: 683–684, 1986
Gion M, Mione R, Dittadi R, Fasan S, Pallini A, Bruscagniin G: Evaluation of Ca 15.3 serum levels in breast cancer patients. J Nucl Med Allied Sci 30: 29–36, 1986
Daver A, Chassevent A, Dalifard J, Cellier P: CA 15.3, ACE, cinetique cellulaire et recepteurs hormonaux dans le cancer du sein.In Advanced Methods in Diagnosis and Therapy, CIS International Symposium, Paris, 1987
Pons-Anicet DMF, Krebs BP, Mira R, Namer M: Value of CA 15.3 in the follow-up of breast cancer patients. Br J Cancer 55: 567–569, 1987
Abbott CEA: EIA monoclonal package insert. Abbott Laboratories, Diagnostics Division, 1984
Thirion B, Barret B: Results of a multicentric study with CA 15.3, a new tumor marker for breast cancer (Abstract).In Gest J (ed): Breast Diseases, IVth International Congress on Senology. Louis Jean, Paris, 1986, p 93
Beard DB, Haskell CM: Carcinoembryonic antigen in breast cancer. Am J Med 80: 241–245, 1986
DeJong-Bakker M, Hart AAM, Persijn JP, Cleton F: Prognostic significance of CEA in breast cancer: A statistical study. Eur J Cancer Clin Oncol 17: 1307–1313, 1981
Waalkes TP, Enterline JP, Shpaer JH, Abeloff MD, Ettinger DS: Biological markers for breast cancer. Cancer 53: 644–651, 1984
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Delarue, J.C., Mouriesse, H., Dubois, F. et al. Markers in breast cancer: Does CEA add to the detection by CA 15.3?. Breast Cancer Res Tr 11, 273–276 (1988). https://doi.org/10.1007/BF01807287
Issue Date:
DOI: https://doi.org/10.1007/BF01807287